Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease

Abstract

Amyloid fibrils composed of peptides as short as six amino acids are effective therapeutics for experimental autoimmune encephalomyelitis (EAE). Immunosuppression arises from at least two pathways: (1) expression of type 1 IFN by pDCs, which were induced by neutrophil extracellular traps arising from the endocytosis of the fibrils; and (2) the reduced expression of IFN-γ, TNF, and IL-6. The two independent pathways stimulated by the fibrils can act in concert to be immunosuppressive in Th1 indications, or in opposition, resulting in inflammation when Th17 T lymphocytes are predominant. The generation of type 1 IFN can be minimized by using polar, nonionizable, amyloidogenic peptides, which are effective in both Th1 and Th17 polarized EAE.

DOI: 10.1084/jem.20140107

Extracted Key Phrases

Cite this paper

@inproceedings{Kurnellas2014MechanismsOA, title={Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease}, author={Michael Phillip Kurnellas and Jill M. Schartner and C. Garrison Fathman and Ann L. Jagger and Lawrence Steinman and Jonathan B. Rothbard}, booktitle={The Journal of experimental medicine}, year={2014} }